So what if Apple didn't make the official list...they probably didn't buy a lot of Apple anyway for 'security reasons" as Apple did not want to disclose its secrets either. Its a two way street. Apple sales were up 48% in Q2. Really does it matter. Maybe most gov employes will buy to do their work as the other products are garbage...just like govt employees are doing everywhere else!
the pros want this to go down..same pattern each day so they trip the stops and help fill their order book so they can get ready to run this over $110 after labor day. They have time , black pools and liquidity!
Apple has posted a smaller-than-expected six percent rise in quarterly revenue, but the good news was that revenue in that period surged 28 percent in greater China despite stiff competition in its third-largest market.
Thanks to a strong performance in the vital for the future Asian market, the tech giant sold 35.2 million iPhones worldwide in the three months up to June.
Chinese iPhones sales jumped about 48 percent and Mac computer sales there rose 39 percent.
Chief Executive Tim Cook told analysts on a conference call that Apple’s Chinese performance was “honestly surprising”.
READ the report and correct your English - There is NO CHINESE GOVT BAN on PURCHASING APPLE PRODUCTS! looks lie some media folks want the stoic to drop
Quiet news time provides opportunity for accumulation. Simply, that's what's going on. Why pay more. Look at where this stock can go....many brokerages and institutions are increasing their positions.
All - December 19th WELLS FARGO Initiated Coverage. Also RBC with outperform in November.
Why doesn't YAHOO note any of this? Go to other sites.
Sentiment: Strong Buy
Wells Fargo initiates coverage on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) with a Outperform rating and $8-$10 valuation range.
The firm comments, "Sunesis' lead compound, vosaroxin, is a novel quinolone derivative in development for relapsed/refractory acute myeloid leukemia (R/R AML). In September 2012 the ongoing vosaroxin Phase III VALOR study passed a major clinical de-risking event, in our view, when the data safety monitoring board (DSMB) recommended VALOR continue to conclusion based on a promising overall survival (OS) signal. Based on our review of vosaroxin and other AML drugs' clinical data, VALOR's statistical assumptions, and expansion of the study's size, we believe VALOR is more likely than not to succeed on its primary endpoint, creating a major potential value inflection for SNSS. During 2013, a final safety analysis and vosaroxin efficacy updates in an elderly front-line study could provide catalysts for SNSS shares ahead of VALOR results in H1 2014E. With a ~$150 million enterprise value and vosaroxin's long-term potential in R/R AML, we believe SNSS is undervalued and see risk/reward as favorable going into VALOR data."
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $4.15 yesterday, with a 52 week range of $1.14-$6.85.
Sentiment: Strong Buy
I hope you stopped out of this company with the downfall of their largest customer HPQ. I only see this stock going down. CHeck out SNSS. Healthcare is where the action is..Been with it from the low 2s and now trying to hold 6.
Sentiment: Strong Sell
After any short spike there's always a gap that needs to be filled. Simply many sold going near the peak at 6.85 and most put stops. Many know that a spike is vulnerable and held off buying until yesterday when the gaps opened up and the price consolidated. Looks good here in the high 5s and low 6s for now.
Sentiment: Strong Buy
Simply, those funds/MMs, etc. are trying to get shares, so they do as much price exploration as they can by taking out stops. Low volume, like yesterday, caused them to push lower to get folks to sell. Volume says it all. I would say most folks are holding and have removed the stops knowing this action is going on. Buy here.
Stock buy backs mostly fail to achieve the desired result. I would rather keep the cash on hand for the company to acquire a value target.
The low volume is dangerous.
THe company is unable to do a stock buy back, not enough cash and what's the point? If the company want it should issue debt...Anyway, I think you could see $1.50. So I would set a staggered limit order to get out with a nice profit. If the company is being targeted for a take-over, the trading firm hired by the interested party is clearly doing a great job to reduce the shareholder's equity.
As mentioned August is an ugly month for this stock.
Agree stock should have moved up with the covering. But with volume so anemic it was a skilled cover & exit. Not sure if the company is dead but there's no-one buying with large lots. This stock may go under $1 soon.
The funds don't want to have this stock on their books for end of 2Q. Selling will continue. Shorts are making $$ hand over fist.